European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- Jun 2026

Navigating the Gold Standard: A Deep Dive into Ph. Eur. Monograph 0478 for “Tablets” In the landscape of pharmaceutical quality control, few documents carry as much authoritative weight as the monographs of the European Pharmacopoeia (Ph. Eur.) . For manufacturers seeking to market oral solid dosage forms within the 38 member states of the European Pharmacopoeia Convention (and beyond, via the CE marking or WHO prequalification), compliance is non-negotiable. At the heart of oral solid dosage regulation lies Monograph 0478: Tablets . While it may seem like a generic entry, Monograph 0478 is the foundational legal text defining what a tablet is, how it must behave, and the tests it must pass before it is deemed safe for human use. Unlike active substance monographs (e.g., Paracetamol or Aspirin), this is a general monograph . It applies to all tablet formulations unless specifically waived or modified by an individual product monograph. This article provides an exhaustive technical breakdown of Ph. Eur. 0478 , covering its scope, analytical requirements (disintegration, dissolution, uniformity), official interpretation, and common pitfalls in Quality Control (QC) laboratories.

1. Scope and Definition: What is a “Tablet” According to Ph. Eur.? Before diving into testing, understanding the legal definition is crucial. According to Monograph 0478, a tablet is defined as:

"Solid dosage forms each containing a single dose of one or more active substances. They are obtained by compressing uniform volumes of particles or by another suitable manufacturing process, such as extrusion, moulding, or freeze-drying."

Key Exclusions and Nuances

Lozenges and pastilles are covered under a separate monograph (Lozenges, 1792). Effervescent tablets are included but have additional specifications (see section 2.9.1). Oral lyophilisates (freeze-dried wafers) are included but require specific hardness/porosity assessments. Gastro-resistant tablets (enteric coated) are included but require specific acid-stage disintegration testing.

The monograph divides tablets into several categories:

Uncoated tablets Coated tablets (film-coated, sugar-coated) Modified-release tablets (prolonged, delayed, pulsatile) Soluble tablets (must dissolve in water within a specific time) Dispersible tablets (uniform dispersion in water) Orodispersible tablets (disintegrate in oral cavity within 3 minutes) European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

Crucial takeaway: The defining characteristic is that the tablet must be homogeneous (dose uniformity) and stable (mechanical resistance to handling).

2. The Core Identity Tests (Identification) Monograph 0478 does not specify which chemical identity test to use (that is left to the individual active substance monograph). However, it mandates that the identification tests for the active substance(s) must be capable of distinguishing the tablet from placebo. Practical implications for QC labs:

If the active substance has a UV maximum at 280 nm, and the excipient also absorbs at 280 nm, UV alone is invalid. You must use HPLC or TLC. For tablets with multiple active substances, the test must confirm each active ingredient. Navigating the Gold Standard: A Deep Dive into Ph

Most manufacturers reference Ph. Eur. 2.9.40 (Uniformity of Dosage Units) as part of the identification strategy, ensuring the correct label claim is present in the correct proportion.

3. The “Big Three” Physical Tests: The Pillars of 0478 The majority of Monograph 0478 is dedicated to mandatory physical tests. Failure in any of these three categories results in batch rejection. A. Uniformity of Mass (Single-dose preparations) Reference: Ph. Eur. 2.9.5 This is the "20 tablets weighed" test.